These include (a) long-term release nuclei containing formaldehyde, (b) selective sealing coatings, and (c) direct release external coatings containing active agents such as DPP-4 or SGLT-2 inhibitors； for trafficking. R type 2 diabetes mellitus.
ITO MASANORI.,EGUSA, KENJI,MESSERSCHMID, ROMAN.,SCHNEIDER, PETER
申请号：
CL2013002505
公开号：
CL2013002505A1
申请日:
2013.08.30
申请国别(地区):
CL
年份:
2014
代理人:
摘要：
The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.COMPOSICION FARMACEUTICA ORAL SOLIDA QUE COMPRENDE A) UN NUCLEO DE LIBERACION PROLONGADA QUE CONTIENE METFORMINA, B) UN RECUBRIMIENTO SELLADOR OPCIONAL, Y C) UN RECUBRIMIENTO EXTERNO DE LIBERACION INMEDIATA QUE COMPRENDE A UN AGENTE ACTIVO, TAL COMO UN INHIBIDOR DE DPP-4 O DE SGLT-2； USO PARA TRATAR DIABETES MELLITUS TIPO 2.
